Genotype and risk of major bleeding during warfarin treatment

Pharmacogenomics

Volumn 15, Issue 16, 2014, Pages 1973-1983

  Kawai, Vivian K ^a   Cunningham, Andrew ^a   Vear, Susan I ^b   Van Driest, Sara L ^a   Oginni, Abimbola ^a   Xu, Hua ^c   Jiang, Min ^c   Li, Chun ^d,e   Denny, Joshua C ^a   Shaffer, Christian ^a   Bowton, Erica ^a   Gage, Brian F ^f   Ray, Wayne A ^a   Roden, Dan M ^a   Stein, C Michael ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CYP2C9; CYP4F2; pharmacogenetics; risk of major bleeding; VKORC1; warfarin

Indexed keywords

AMIODARONE; ANTITHROMBOCYTIC AGENT; CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 4F2; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1; VITAMIN K GROUP; WARFARIN; CYP4F2 PROTEIN, HUMAN; VKORC1 PROTEIN, HUMAN;

ADULT; AFRICAN AMERICAN; ARTICLE; BLEEDING; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CAUCASIAN; CHRONIC KIDNEY DISEASE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; ELECTRONIC MEDICAL RECORD; EPISTAXIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; GENOTYPING TECHNIQUE; HEART ATRIUM FIBRILLATION; HEMARTHROSIS; HEMATOMA; HEMOPERICARDIUM; HEMOPTYSIS; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; PHARMACOGENETICS; PREVALENCE; RETROPERITONEAL HEMORRHAGE; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT INDICATION; VENOUS THROMBOEMBOLISM; AGED; CHEMICALLY INDUCED; DOSE RESPONSE; ETHNIC GROUP; GENETIC ASSOCIATION; GENETICS; HEALTH CARE FACILITY; HEMORRHAGE; MIDDLE AGED;

ADULT; AGED; BIOLOGICAL SPECIMEN BANKS; CYTOCHROME P-450 CYP2C9; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHNIC GROUPS; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC VARIATION; GENOTYPE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; VITAMIN K EPOXIDE REDUCTASES; WARFARIN;

EID: 84919819892     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.153     Document Type: Article

References (42)

1. Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ. Cardiovasc. Qual. Outcomes 5(5), 615-621 (2012
2. Keeling D, Baglin T, Tait C, et al. Guidelines on oral anticoagulation with warfarin-fourth edition. Br. J. Haematol. 154(3), 311-324 (2011
3. Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-Term prevention of recurrent venous thromboembolism. N. Engl. J. Med. 349(7), 631-639 (2003
4. Reynolds MW, Fahrbach K, Hauch O, et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest 126(6), 1938-1945 (2004
5. Loebstein R, Yonath H, Peleg D, et al. Interindividual variability in sensitivity to warfarin-nature or nurture?. Clin. Pharmacol. Ther. 70(2), 159-164 (2001
6. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb. Haemost. 91(1), 87-94 (2004
7. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352(22), 2285-2293 (2005
8. Takeuchi F, McGinnis R, Bourgeois S, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5(3), e1000433 (2009
9. The International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360(8), 753-764 (2009
10. Lindh JD, Lundgren S, Holm L, Alfredsson L, Rane A. Several-fold increase in risk of overanticoagulation by CYP2C9 mutations. Clin. Pharmacol. Ther. 78(5), 540-550 (2005
11. Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation. N. Engl. J. Med. 358(10), 999-1008 (2008
12. Ferder NS, Eby CS, Deych E, et al. Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. J. Thromb. Haemost. 8(1), 95-100 (2010
13. Johnson JA, Gong L, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin. Pharmacol. Ther. 90(4), 625-629 (2011
14. McClain MR, Palomaki GE, Piper M, Haddow JE. A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding. Genet. Med. 10(2), 89-98 (2008
15. Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch. Intern. Med. 167(13), 1414-1419 (2007
16. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353(9154), 717-719 (1999
17. Margaglione M, Colaizzo D, DAndrea G, et al. Genetic modulation of oral anticoagulation with warfarin. Thromb. Haemost. 84(5), 775-778 (2000
18. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287(13), 1690-1698 (2002
19. Limdi NA, McGwin G, Goldstein JA, et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin. Pharmacol. Ther. 83(2), 312-321 (2008
20. Yang J, Chen Y, Li X, et al. Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-Treated patients: A systematic review and meta-Analysis. Int. J. Cardiol. 168(4), 4234-4243 (2013
21. Li C, Schwarz UI, Ritchie MD, Roden DM, Stein CM, Kurnik D. Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood 113(17), 3925-3930 (2009
22. Epstein RS, Moyer TP, Aubert RE, et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J. Am. Coll. Cardiol. 55(25), 2804-2812 (2010
23. Roden DM, Pulley JM, Basford MA, et al. Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin. Pharmacol. Ther. 84(3), 362-369 (2008
24. Xu H, Stenner SP, Doan S, Johnson KB, Waitman LR, Denny JC. MedEx: a medication information extraction system for clinical narratives. J. Am. Med. Inform. Assoc. 17(1), 19-24 (2010
25. Fihn SD, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Ann. Intern. Med. 118(7), 511-520 (1993
26. Cunningham A, Stein CM, Chung CP, Daugherty JR, Smalley WE, Ray WA. An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol. Drug Saf. 20(6), 560-566 (2011
27. Roth JA, Boudreau D, Fujii MM, et al. Genetic risk factors for major bleeding in patients treated with warfarin in a. community setting. Clin. Pharmacol. The. 95(6), 636-643 (2013
28. Kealey C, Chen Z, Christie J, et al. Warfarin and cytochrome P450 2C9 genotype: possible ethnic variation in warfarin sensitivity. Pharmacogenomics 8(3), 217-225 (2007
29. Meckley LM, Wittkowsky AK, Rieder MJ, Rettie AE, Veenstra DL. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-Treated patients. Thromb. Haemost. 100(2), 229-239 (2008
30. Kimmel SE, French B, Kasner SE, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N. Engl. J. Med. 369(24), 2283-2293 (2013
31. Pirmohamed M, Burnside G, Eriksson N, et al. A randomized trial of genotype-guided dosing of warfarin. N. Engl. J. Med. 369(24), 2294-2303 (2013
32. Furie B. Do pharmacogenetics have a role in the dosing of vitamin K antagonists?. N. Engl. J. Med. 369(24), 2345-2346 (2013
33. Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin. Pharmacokinet. 40(8), 587-603 (2001
34. Millican EA, Lenzini PA, Milligan PE, et al. Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood 110(5), 1511-1515 (2007
35. Lindh JD, Holm L, Andersson ML, Rane A. Influence of CYP2C9 genotype on warfarin dose requirements-A systematic review and meta-Analysis. Eur. J. Clin. Pharmacol. 65(4), 365-375 (2009
36. Limdi NA, Arnett DK, Goldstein JA, et al. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics 9(5), 511-526 (2008
37. Schelleman H, Chen Z, Kealey C, et al. Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians. Clin. Pharmacol. Ther. 81(5), 742-747 (2007
38. Lund K, Gaffney D, Spooner R, Etherington AM, Tansey P, Tait RC. Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin international normalized ratio control and bleeding rates. Br. J. Haematol. 158(2), 256-261 (2012
39. Limdi NA, Wiener H, Goldstein JA, Acton RT, Beasley TM. Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy. Blood Cells. Mol. Dis. 43(1), 119-128 (2009
40. Horne BD, Lenzini PA, Wadelius M, et al. Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. Thromb. Haemost. 107(2), 232-240 (2012
41. Bowton E, Field JR, Wang S, et al. Biobanks and electronic medical records: enabling cost-effective research. Sci. Transl. Med. 6(234), 234cm3 (2014
42. Ramirez AH, Shi Y, Schildcrout JS, et al. Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record. Pharmacogenomics 13(4), 407-418 (2012